An Alexion Pharmaceuticals Inc. patent describes new complement C1s subcomponent (C1S) inhibitors potentially useful for the treatment of immune thrombocytopenia purpura, lupus nephritis, amyotrophic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback